MyCo-Triacet II, Mycolog II (triamcinolone/nystatin) dosing, indications, interactions, adverse effects, and more

Sections

Sections triamcinolone acetonide injectable suspension/nystatin
Dosing & Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology
Images
Patient Handout
Formulary

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

triamcinolone/nystatin

topical cream/ointment

(0.1%/100,000units)/g

Cutaneous Candidiasis

Apply cream/ointment BID; discontinue therapy when infection is under control or if symptoms persist for >25 days

Dosage Forms & Strengths

triamcinolone/nystatin

topical cream/ointment

(0.1%/100,000units)/g

Cutaneous Candidiasis

As adults; apply cream/ointment BID; discontinue therapy when infection is under control or if symptoms persist for >25 days

Interaction Checker

Enter a drug name and triamcinolone acetonide injectable suspension/nystatin

No Results

No Interactions Found

Interactions Found

Contraindicated

Serious - Use Alternative

Significant - Monitor Closely

Minor

All Interactions Sort By:

Due to system maintenance, the drug interactions feature you are attempting to access is temporarily unavailable. Please try again later.

Frequency Not Defined

Blistering

Burning

Dryness

Acniform eruptions

Excessive discoloring of the skin

Excessive hair growth (especially on face)

Hair loss (especially on scalp)

Inflammation around the mouth

Inflammation of hair follicles

Irritation

Itching

Peeling

Prickly heat

Striae

Secondary infection

Skin inflammation

Softening of the skin

Stretch marks

Stretching or thinning of the skin

Contraindications

Hypersensitivity

Cautions

For topical use only

Not for ophthalmic use

Avoid contact with eyes

Patient should report any signs of adverse reactions

Systemic absorption of topical corticosteroids has produced reversible hypothalmic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients

Conditions that augment systemic absorption include application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings

Patients receiving a large dose of any potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis; if HPA axis suppression or elevation of body temperature occurs, make attempt to withdraw drug, reduce frequency of application, or substitute for less potent steroid

Recovery of HPA axis function and thermal homeostasis are generally prompt and complete upon discontinuation of drug; infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids

Children may absorb proportionally larger amounts of topical corticosteroids and thus may be more susceptible to systemic toxicity

If irritation or hypersensitivity develops with combination of nystatin and triamcinolone acetonide, discontinue treatment and institute appropriate therapy

Pregnancy & Lactation

Pregnancy Category: unknown

Lactation: unknown if excreted in breast milk

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Triamcinolone potency

Medium

Very-high: clobetasol, diflorasone diacetate ointment 0.05%, halobetasol

High: betamethasone dipropionate 0.05%, amcinonide, fluocinonide, desoximetasone, mometasone, diflorasone emollient 0.05%, halcinonide

Medium: triamcinolone, betamethasone valerate 0.1%, fluticasone, flurandrenolide, fluocinolone 0.025%, hydrocortisone

Mild: hydrocortisone 0.5, 1, 2.5% base, desonide, alclometasone

Mechanism of Action

Nystatin: Antifungal activity

Triamcinolone: Corticosteroid; elicits antipruritic and anti-inflammatory effects

Images

No images available for this drug.

Patient Handout

A Patient Handout is not currently available for this monograph.

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Create Your List of Plans

Adding plans allows you to:

View the formulary and any restrictions for each plan.
Manage and view all your plans together – even plans in different states.
Compare formulary status to other drugs in the same class.
Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

View explanations for tiers and restrictions

Tier	Description
1	This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2	This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC	NOT COVERED – Drugs that are not covered by the plan.

Code	Definition
PA	Prior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL	Quantity Limits Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST	Step Therapy Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR	Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]